Loading news...
Gerresheimer on Tuesday again deferred the release of 2025 financial statements to June, citing a probe into its business deals, a delay that is now set to cost the German medical products maker its place on the Deutsche Boerse's SDAX index.
Diamond Hill International Strategy returned 3.87% (net of fees) and the MSCI ACWI ex USA Index returned 5.05%. Sumitomo Densetsu, a Japanese electrical contractor, benefited from a takeover bid by Daiwa House, whose tender offer at a premium price drove the stock higher. Stock selection in information technology and industrials contributed, along with our overweight to communication services.
Medical equipment maker Gerresheimer said on Tuesday it had appointed Uwe Röhrhoff as interim CEO, effective November 1, 2025. He succeeds Dietmar Siemssen, who will step down as CEO by mutual agreement with the company's supervisory board on October 31.
Medical equipment maker Gerresheimer said it has obtained the initial findings from an investigation by an external law firm into the recognition of revenue and profit from bill-and-hold agreements in the 2024 financial year.
Gerresheimer AG (OTCPK:GRRMY) Q3 2025 Earnings Call October 9, 2025 2:30 AM EDT Company Participants Guido Pickert - Head of Investor Relations Dietmar Siemssen - CEO, Chairman of the Management Board and CEO of Plastics, Devices & Advanced Technologies Division Wolf Lehmann - CFO & Member of the Management Board Conference Call Participants Edward Hall - Stifel, Nicolaus & Company, Incorporated, Research Division Olivier Calvet - UBS Investment Bank, Research Division David Adlington - JPMorgan Chase & Co, Research Division Anna Snopkowski - KeyBanc Capital Markets Inc., Research Division Presentation Guido Pickert Head of Investor Relations Good morning, everyone, and welcome to our presentation of our preliminary Q3 2025 results. With us today are our CEO, Dietmar Siemssen; and our new CFO, Wolf Lehmann, who will lead you through our Q3 development and the financials.
Shares in Gerresheimer fell 11% on Thursday, a day after the German packaging and medical equipment maker cut its 2025 guidance for the third time this year.
German packaging and medical equipment maker Gerresheimer cut its 2025 guidance again on Wednesday, now expecting organic revenues to decline between 2-4% as third quarter results fell below expectations.
Shares in medical equipment maker Gerresheimer plunged as much as 38% on Wednesday after Germany's financial regulator said it was investigating suspected accounting rule violations.
Active Ownership, a major shareholder in Gerresheimer , said on Thursday it saw major potential for value creation at the German packaging and medical equipment specialist and called for a strategic review, a second activist investor to do so.
Shares of German packaging and medical equipment maker Gerresheimer jumped around 4% in early trading on Tuesday after the company announced plans to sell its moulded glass business late on Monday.
German packaging and medical equipment maker Gerresheimer has ended discussions on a potential sale of the company, it said on Wednesday evening.
German packaging and medical equipment maker Gerresheimer cut its revenue guidance for 2025 for a second time on Thursday, seeing continued weak demand in the cosmetic and oral liquids markets.
LONDON--(BUSINESS WIRE)--Asset Value Investors (“AVI”) has sent an open letter to the Supervisory Board of Gerresheimer AG (“Gerresheimer”) calling for it to make changes to its financial leadership. You can find the published letter here. AVI invested in Gerresheimer in 2024 and manages a 3.5% stake on behalf of institutional clients. Gerresheimer holds a valuable position in the Containment Solutions & Delivery Systems industry, with high barriers to entry and attractive long-term growth.
London-based investment fund Asset Value Investors has asked German medical packaging maker Gerresheimer to take steps to restore its market value, it said on Thursday.
German packaging and medical equipment maker Gerresheimer cut its guidance for 2025 on Monday, citing continued weak demand in the cosmetics sector and a decline in demand for containment solutions for liquid medications.
Gerresheimer's strategic shift to value-driven solutions in pharma packaging supports higher margins and justifies a premium valuation over traditional packaging peers. Despite a weak Q1 with net loss and negative cash flow, management guides for strong revenue and margin recovery, projecting 22% EBITDA margin for FY 2025. Long-term outlook is robust: Management expects 8-10% annual revenue growth, EBITDA margin expansion, and double-digit EPS growth as Bormioli integration delivers synergies.
Gerresheimer AG (OTCPK:GRRMF) Q1 2025 Earnings Conference Call April 11, 2025 4:00 AM ET Company Participants Guido Pickert - Vice President, Corporate Investor Relations Dietmar Siemssen - Chief Executive Officer Bernd Metzner - Chief Financial Officer Conference Call Participants James Vane-Tempest - Jefferies Victoria Lambert - Berenberg David Adlington - JPMorgan Odysseas Manesiotis - BNP Paribas Olivier Calvet - UBS Edward Hall - Stifel Delphine Le Louet - Bernstein Alexander Galitsa - HAIB Operator Ladies and gentlemen, welcome to the publication Q1 2025 Results Conference Call. I am George, the Chorus Call operator.
German packaging and medical equipment maker Gerresheimer reported a lower organic core profit for the first quarter on Friday, hit by continued lower demand in moulded glass and shift in syringe revenues into later quarters.
KKR has abandoned a private equity consortium discussing a takeover of Gerresheimer AG , Bloomberg News reported on Thursday, citing people familiar with the matter.